Cutler Group’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-11,400
Closed -$5K 5063
2022
Q1
$5K Buy
+11,400
New +$3.52M ﹤0.01% 4101
2020
Q3
Sell
-4,000
Closed -$11K 4742
2020
Q2
$11K Buy
+4,000
New +$638K ﹤0.01% 2798
2017
Q3
Sell
-1,700
Closed -$20K 5976
2017
Q2
$20K Sell
1,700
-2,700
-61% -$249K ﹤0.01% 3401
2017
Q1
$52K Buy
4,400
+3,900
+780% +$331K ﹤0.01% 2371
2016
Q4
$1K Sell
500
-3,800
-88% -$289K ﹤0.01% 5925
2016
Q3
$4K Buy
+4,300
New +$360K ﹤0.01% 5108

Other funds holding CRL

Cutler Group's CRL Position: Q4 2017 in Review

Cutler Group sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 394 shares — an estimated $42K sold.

Cutler Group first reported a position in CRL in Q4 2015 and held it in 4 quarters. The position peaked at $136K in Q2 2016. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Cutler Group reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 394 Charles River Laboratories shares in Q4 2017, an estimated $42K.
  • Cutler Group first reported a position in Charles River Laboratories in Q4 2015 and held it in 4 quarters.
  • Cutler Group's Charles River Laboratories position peaked at $136K in Q2 2016.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.